about
Phagocytosed Clofazimine Biocrystals Can Modulate Innate Immune Signaling by Inhibiting TNFα and Boosting IL-1RA SecretionRepositioning Clofazimine as a Macrophage-Targeting Photoacoustic Contrast Agent.Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organizationThe M. tuberculosis HAD phosphatase (Rv3042c) interacts with host proteins and is inhibited by ClofazimineAntiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug RepositioningEfficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans DiseaseA high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosisClofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.Clofazimine modulates the expression of lipid metabolism proteins in Mycobacterium leprae-infected macrophages.Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.A far-red fluorescent probe for flow cytometry and image-based functional studies of xenobiotic sequestering macrophagesEvidence for the presence of clofazimine and its distribution in the healthy mouse brain.Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosisA Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug LibraryChemical Analysis of Drug Biocrystals: A Role for Counterion Transport Pathways in Intracellular Drug Disposition.Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical modelsAn Antifungal Combination Matrix Identifies a Rich Pool of Adjuvant Molecules that Enhance Drug Activity against Diverse Fungal PathogensStreptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.Antiinfectives targeting enzymes and the proton motive force.Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in miceClofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration responseClofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory StateStringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo.Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.Is repositioning of drugs a viable alternative in the treatment of tuberculosis?The eradication of leprosy: molecular modeling techniques for novel drug discovery.Current bioanalytical methods for pharmacokinetic studies of drugs used in neglected tropical diseases.Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Impact of intracellular ion channels on cancer development and progression.Antimycobacterial and anti-inflammatory activities of substituted chalcones focusing on an anti-tuberculosis dual treatment approach.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.The Roles of Mitochondrial Cation Channels Under Physiological Conditions and in Cancer.Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo.Insight into the interaction of antitubercular and anticancer compound clofazimine with human serum albumin: spectroscopy and molecular modelling.Discovery of Indeno[1,2-c]quinoline Derivatives as Potent Dual Antituberculosis and Anti-Inflammatory Agents.Varying effects of common tuberculosis drugs on enhancing clofazimine activity in vitro.Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
P2860
Q27301088-88B13333-E8B4-45C9-A932-37CCA072514BQ27327281-3E6BFC49-4B10-48CA-B9BA-F25E07C00D57Q28484367-E0251D5F-234B-48F2-AD49-59666AB06F0DQ28486645-35B76CEB-7B5B-461B-B8F7-17FB528BD89FQ28547217-9A364C91-380A-4C50-9253-67344CD66384Q28552524-5942D4B0-999E-43A8-87E0-6FB7DC555328Q30361870-2C8F6F68-B513-4D72-B7D3-5DCFCB6097D9Q34331039-4907EAE8-7885-4862-BEFA-434D430350B2Q34511138-ED6FC51B-E631-4B0B-97FA-D0957E0C53BFQ35650795-26D5591E-E3C6-4FB4-81AC-DDA6A0B9CA34Q35673729-A1CD7AEA-B3DA-4676-8322-250D55F4D30BQ35712475-AA79FC8E-A86B-4081-B887-02B7B25AADCEQ35962789-F41D06F0-8D0F-491C-A621-C6387C4DCF8FQ36034530-0DC63775-1415-4671-B1F9-C47AED6A4C19Q36057273-FC1C4A17-8915-443F-88EE-D4B76A89681BQ36158384-105DAE44-430C-4083-8376-B7CA74E672C1Q36304381-F56F3A19-374A-4557-942C-18AD5436383EQ36364079-B718A6FA-C062-41E4-9939-C7CFAB19E260Q36419761-3628DACF-EC6B-479C-9713-650978A7A63CQ36558489-95A0490C-02BC-4B78-ABA8-1B19DA91B0FCQ36571826-A70BC8B7-8B3F-4C08-8481-A47F7FB87B76Q36667157-4D60CCE4-4A49-4430-B038-2AEF8EF3B02DQ36933396-5A7A1491-E35A-4C5B-87D3-7D05BE165420Q37358614-8F6E66BA-9850-49F7-B818-45E2558CF114Q37516784-A28A8882-CFDE-465D-A28B-752DB9B9ED4BQ37720810-81DD1102-A80E-4D33-93AF-650BFC5CC999Q38053000-5A7D70BF-B067-4720-8672-3F210889E7C5Q38127263-092CF606-5273-4AF9-AA90-8B9407E7AE5FQ38235444-2FF5F9F1-884D-4EAF-BAB7-30BE7ED5566BQ38404398-32757BBE-E73E-4047-82A7-0687B8B80055Q38792870-3197B7AB-DE83-475D-8F60-DF2701BC11F0Q38862322-87F714CC-8CDE-4735-93AD-4582572D5A79Q38878123-1E8B58B1-300B-4461-98A3-AF7E6E21B1C7Q38995175-C3F4449C-BFFE-40CA-8E7F-FA7CDE51CB09Q39044112-ECB876A1-0FDC-4A90-AECB-0FD34CD39B8CQ39231486-7D9EB3BA-F2A9-449C-9166-509FEF2272C2Q39748489-8280DC02-8510-4A05-9C2C-6173FE7192C9Q40052236-5BF855EF-0E4D-4122-AD87-F825CABE7C3AQ40237873-B0D4F966-2138-4628-9710-9256CE85F03EQ40280093-9A8D777B-EE7A-4C4C-B356-60509543DC9B
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Clofazimine: current status and future prospects.
@ast
Clofazimine: current status and future prospects.
@en
Clofazimine: current status and future prospects.
@nl
type
label
Clofazimine: current status and future prospects.
@ast
Clofazimine: current status and future prospects.
@en
Clofazimine: current status and future prospects.
@nl
prefLabel
Clofazimine: current status and future prospects.
@ast
Clofazimine: current status and future prospects.
@en
Clofazimine: current status and future prospects.
@nl
P2093
P2860
P356
P1476
Clofazimine: current status and future prospects.
@en
P2093
Helen C Steel
Moloko C Cholo
P B Fourie
Ronald Anderson
Willem A Germishuizen
P2860
P304
P356
10.1093/JAC/DKR444
P407
P577
2011-10-20T00:00:00Z